Fig. 4: Vincristine induces resistance in RMS cells through BID and BAK inhibition by MCL-1. | Cell Death & Disease

Fig. 4: Vincristine induces resistance in RMS cells through BID and BAK inhibition by MCL-1.

From: Sequential combinations of chemotherapeutic agents with BH3 mimetics to treat rhabdomyosarcoma and avoid resistance

Fig. 4: Vincristine induces resistance in RMS cells through BID and BAK inhibition by MCL-1.

a Left panel: Western blot results of the unbound fraction after MCL-1 immunoprecipitation. Right panel: MCL-1 levels in the initial cell lysates. High efficiency of MCL-1 immunoprecipitation compared to Rabbit IgG control antibody. b Western blot results of the co-immunoprecipitation between MCL-1 and tBID in control conditions and after 1 nM vincristine treatment for 36 h. Results showed a significant increase in tBID and MCL-1 binding after vincristine treatment. c Western blot results of the co-immunoprecipitation between MCL-1 and BAK in control conditions, after 1 nM vincristine treatment and after the sequential combination of 1 nM vincristine and 1 µM S63845 for 36 h. Results showed a significant increase in BAK and MCL-1 binding after vincristine treatment, which was decreased below control levels after the addition of S63845. Values indicate mean values ± SEM from at least three independent experiments. **p < 0.01, *p < 0.05.

Back to article page